Viatris

CompanyUnited States

Viatris develops 4 assets, the furthest approved (atorvastatin in angina). Mostly small molecule acting on AMPK signalling, lipid and ceramide metabolism and HMGCR; based in the United States.

Assets
4
Furthest
Approved
Trials
94
Signals
0

Pipeline

4

  • atorvastatin

    HMG-CoA reductase inhibitor that suppresses cholesterol biosynthesis and lowers plasma LDL levels

    ApprovedSmall moleculeAMPK signallingLipid and ceramide metabolismanginacoronary heart disease

  • celecoxib

    Selective cyclooxygenase-2 inhibitor reducing prostaglandin synthesis to relieve pain and inflammation

    ApprovedSmall moleculeInflammationPTGS2acute painadenomatous polyposis coli

  • phenytoin

    Voltage-gated sodium channel blocker that stabilizes neuronal membranes

    ApprovedSmall moleculeSCN5ASCN1Aseizures

1 more asset

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms8
  • Trials98
  • Signals1
  • Similar companies6

Updated 7 Oct 2026 · 115 sources

Intelligence